Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088894894> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W3088894894 endingPage "S873" @default.
- W3088894894 startingPage "S872" @default.
- W3088894894 abstract "Afatinib is an effective treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC), however, its toxicities often require dose modifications. The aim of this study was to assess the efficacy and safety of low dose afatinib monotherapy in patients with EGFR mutation-positive NSCLC. This study was a multicenter, single-arm, open-label phase II trial. Treatment-naïve patients with advanced NSCLC positive for common EGFR mutations received afatinib in a dose of 20mg/day. The same dose was continued unless the tumor had grown. The primary endpoint (PE) was progression-free survival (PFS) The threshold median PFS was 9.2 months and the expected median PFS 13.8 months. From March 2017 through September 2018, 53 patients were enrolled from 21 institutions in Japan. The median age was 70 years (range, 37–85), and 28 patients (52.8%) were women. EGFR mutation subtypes included exon 19 deletion (56.6%) and L858R point mutation (43.4%). Most patients had a performance status of 0 or 1 (86.8%). As of the data cut-off date of March 2020, the median follow-up was 20.8 months. The median PFS, time to treatment failure and overall survival were 12.6 months (95% CI: 9.7–14.3), 18.6 months (95%CI: 16.0-21.2) and not reached. The PE was met. The objective response and the disease control was 66.6% (95% CI: 51.7-78.5) and 92.5% (95% CI: 81.8-97.9). Adverse events (AEs) of grade 3 or higher occurred in 12 patients (22.6%) including diarrhea in 4 patients (7.5%) that was lower than that observed in phase III studies of afatinib using 40 mg. Eight of 19 patients (42.1%) had T790M resistant mutation. Afatinib plasma concentrations at 9 days after the start of administration had no correlations with clinical outcomes and AEs including diarrhea. Low dose afatinib would be considered as one of standard therapy for EGFR mutation-positive NSCLCs because of promising clinical efficacy and good tolerability." @default.
- W3088894894 created "2020-10-01" @default.
- W3088894894 creator A5000850367 @default.
- W3088894894 creator A5002582387 @default.
- W3088894894 creator A5012646269 @default.
- W3088894894 creator A5021722390 @default.
- W3088894894 creator A5023890444 @default.
- W3088894894 creator A5034162457 @default.
- W3088894894 creator A5037351215 @default.
- W3088894894 creator A5038270737 @default.
- W3088894894 creator A5040162534 @default.
- W3088894894 creator A5040576511 @default.
- W3088894894 creator A5045893818 @default.
- W3088894894 creator A5047275051 @default.
- W3088894894 creator A5052686953 @default.
- W3088894894 creator A5063044564 @default.
- W3088894894 creator A5065387771 @default.
- W3088894894 creator A5068149602 @default.
- W3088894894 creator A5068414206 @default.
- W3088894894 creator A5078647935 @default.
- W3088894894 creator A5083502759 @default.
- W3088894894 creator A5087540054 @default.
- W3088894894 date "2020-09-01" @default.
- W3088894894 modified "2023-09-28" @default.
- W3088894894 title "1365P A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)" @default.
- W3088894894 doi "https://doi.org/10.1016/j.annonc.2020.08.1679" @default.
- W3088894894 hasPublicationYear "2020" @default.
- W3088894894 type Work @default.
- W3088894894 sameAs 3088894894 @default.
- W3088894894 citedByCount "0" @default.
- W3088894894 crossrefType "journal-article" @default.
- W3088894894 hasAuthorship W3088894894A5000850367 @default.
- W3088894894 hasAuthorship W3088894894A5002582387 @default.
- W3088894894 hasAuthorship W3088894894A5012646269 @default.
- W3088894894 hasAuthorship W3088894894A5021722390 @default.
- W3088894894 hasAuthorship W3088894894A5023890444 @default.
- W3088894894 hasAuthorship W3088894894A5034162457 @default.
- W3088894894 hasAuthorship W3088894894A5037351215 @default.
- W3088894894 hasAuthorship W3088894894A5038270737 @default.
- W3088894894 hasAuthorship W3088894894A5040162534 @default.
- W3088894894 hasAuthorship W3088894894A5040576511 @default.
- W3088894894 hasAuthorship W3088894894A5045893818 @default.
- W3088894894 hasAuthorship W3088894894A5047275051 @default.
- W3088894894 hasAuthorship W3088894894A5052686953 @default.
- W3088894894 hasAuthorship W3088894894A5063044564 @default.
- W3088894894 hasAuthorship W3088894894A5065387771 @default.
- W3088894894 hasAuthorship W3088894894A5068149602 @default.
- W3088894894 hasAuthorship W3088894894A5068414206 @default.
- W3088894894 hasAuthorship W3088894894A5078647935 @default.
- W3088894894 hasAuthorship W3088894894A5083502759 @default.
- W3088894894 hasAuthorship W3088894894A5087540054 @default.
- W3088894894 hasBestOaLocation W30888948941 @default.
- W3088894894 hasConcept C121608353 @default.
- W3088894894 hasConcept C126322002 @default.
- W3088894894 hasConcept C141071460 @default.
- W3088894894 hasConcept C143998085 @default.
- W3088894894 hasConcept C203092338 @default.
- W3088894894 hasConcept C2776256026 @default.
- W3088894894 hasConcept C2779438470 @default.
- W3088894894 hasConcept C2780580887 @default.
- W3088894894 hasConcept C2780586478 @default.
- W3088894894 hasConcept C31760486 @default.
- W3088894894 hasConcept C535046627 @default.
- W3088894894 hasConcept C71924100 @default.
- W3088894894 hasConcept C90924648 @default.
- W3088894894 hasConceptScore W3088894894C121608353 @default.
- W3088894894 hasConceptScore W3088894894C126322002 @default.
- W3088894894 hasConceptScore W3088894894C141071460 @default.
- W3088894894 hasConceptScore W3088894894C143998085 @default.
- W3088894894 hasConceptScore W3088894894C203092338 @default.
- W3088894894 hasConceptScore W3088894894C2776256026 @default.
- W3088894894 hasConceptScore W3088894894C2779438470 @default.
- W3088894894 hasConceptScore W3088894894C2780580887 @default.
- W3088894894 hasConceptScore W3088894894C2780586478 @default.
- W3088894894 hasConceptScore W3088894894C31760486 @default.
- W3088894894 hasConceptScore W3088894894C535046627 @default.
- W3088894894 hasConceptScore W3088894894C71924100 @default.
- W3088894894 hasConceptScore W3088894894C90924648 @default.
- W3088894894 hasLocation W30888948941 @default.
- W3088894894 hasOpenAccess W3088894894 @default.
- W3088894894 hasPrimaryLocation W30888948941 @default.
- W3088894894 hasRelatedWork W2888534976 @default.
- W3088894894 hasRelatedWork W2889523320 @default.
- W3088894894 hasRelatedWork W2906574801 @default.
- W3088894894 hasRelatedWork W3034828127 @default.
- W3088894894 hasRelatedWork W3036162643 @default.
- W3088894894 hasRelatedWork W3088894894 @default.
- W3088894894 hasRelatedWork W3171195357 @default.
- W3088894894 hasRelatedWork W4224237029 @default.
- W3088894894 hasRelatedWork W4366082921 @default.
- W3088894894 hasRelatedWork W1931533321 @default.
- W3088894894 hasVolume "31" @default.
- W3088894894 isParatext "false" @default.
- W3088894894 isRetracted "false" @default.
- W3088894894 magId "3088894894" @default.
- W3088894894 workType "article" @default.